Amyloid-Journal of Protein Folding Disorders

Papers
(The H4-Index of Amyloid-Journal of Protein Folding Disorders is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
A second case of liraglutide-type localised amyloidosis219
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies201
A case of asymmetric insulin-derived localised amyloid deposition associated with long-acting insulin analog administration95
Changes in the amyloid editorial board members and in editor positions81
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey62
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis40
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study34
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases28
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange26
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging24
Survey of amyloidosis cases among different free-living wild and zoo animals24
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains21
Early cardiovascular autonomic failure in ATTRv predicts poor prognosis and may respond to disease-modifying therapy19
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis18
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition17
Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis16
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy16
0.067524909973145